The proline 12 alanine substitution in the peroxisome proliferator--activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo.

Lipoprotein lipase (LPL) plays a key role in lipid metabolism by hydrolyzing triglycerides in circulating lipoproteins. Low LPL activity has been linked to coronary artery disease (CAD), but the factors influencing LPL expression are not completely understood. Peroxisome proliferator--activated receptor (PPAR)-gamma is a nuclear receptor regulating lipid and glucose metabolism, and a PPAR-responsive element is present in the LPL promoter. We determined the Pro12Ala polymorphism in the PPAR-gamma2 gene in 194 male CAD patients because this allele is associated with decreased PPAR activity and reduced LPL promoter activity in vitro. Presence of 12Ala was associated with 20% lower LPL activity in postheparin plasma (141 +/- 58 vs. 177 +/- 77 nmol.ml(-1).min(-1), P < 0.005). Remarkably, the influence of 12Ala on LPL was greater than that of the frequent polymorphisms (HindIII +9%, PvuII +/- 0%, 447stop +12%) in the LPL gene itself. To confirm these results in a different group of patients, we analyzed 100 diabetic patients in whom the 12Ala allele was also associated with lower LPL activity (12Ala: 132 +/- 88 vs. 190 +/- 129 nmol.ml(-1).min(-1), P < 0.05). Our data demonstrate that the Pro12Ala substitution in PPAR-gamma2 is associated with lower LPL activity in vivo and provides a new target for the analysis of genetic influences on LPL activity and CAD risk.

[1]  J. Carlquist,et al.  Association of lipoprotein lipase gene polymorphisms with coronary artery disease. , 1999, Journal of the American College of Cardiology.

[2]  J. Kobayashi,et al.  Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. , 2000, British journal of clinical pharmacology.

[3]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[4]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[5]  E S Lander,et al.  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.

[6]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[7]  M. Hayden,et al.  Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. , 1996, The New England journal of medicine.

[8]  A. Zwinderman,et al.  Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris , 2000 .

[9]  R. Zechner,et al.  Role of Macrophage-Derived Lipoprotein Lipase in Lipoprotein Metabolism and Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  K. Dugi,et al.  Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery disease. , 2002, Atherosclerosis.

[11]  M. Taskinen.  Lipoprotein lipase in diabetes. , 1987, Diabetes/metabolism reviews.

[12]  K. Silver,et al.  Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation , 1997 .

[13]  E. Boerwinkle,et al.  Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser447-Stop Substitution in the Lipoprotein Lipase Gene , 1997 .

[14]  K. Silver,et al.  Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. , 1997, Biochemical and biophysical research communications.

[15]  K. Dugi,et al.  Structure, function and role of lipoprotein lipase in lipoprotein metabolism. , 1994, Current opinion in lipidology.

[16]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[17]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[18]  B. Nordestgaard,et al.  Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  E. Boerwinkle,et al.  Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. , 1997, Circulation.

[20]  A. Pfeiffer,et al.  Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.

[21]  B. McManus,et al.  Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. , 2000, Journal of lipid research.

[22]  D. Arveiler,et al.  Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. , 1995, Journal of lipid research.